Akebia Therapeutics, Inc. (AKBA) Analysts See $-0.51 EPS

July 14, 2018 - By Elizabeth Jones

Akebia Therapeutics, Inc. (NASDAQ:AKBA) LogoInvestors sentiment increased to 1.9 in 2018 Q1. Its up 0.27, from 1.63 in 2017Q4. It improved, as 14 investors sold Akebia Therapeutics, Inc. shares while 28 reduced holdings. 37 funds opened positions while 43 raised stakes. 39.14 million shares or 29.30% more from 30.27 million shares in 2017Q4 were reported.
Aqr Capital Management Ltd Liability accumulated 22,622 shares or 0% of the stock. Royal Bancshares Of Canada invested 0% of its portfolio in Akebia Therapeutics, Inc. (NASDAQ:AKBA). Us Bancorporation De holds 0% of its portfolio in Akebia Therapeutics, Inc. (NASDAQ:AKBA) for 6,114 shares. Rhumbline Advisers has invested 0% in Akebia Therapeutics, Inc. (NASDAQ:AKBA). Artal Group reported 475,000 shares. Zurcher Kantonalbank (Zurich Cantonalbank) accumulated 0% or 2,101 shares. Fmr Limited Liability has invested 0% in Akebia Therapeutics, Inc. (NASDAQ:AKBA). Spark Investment Mgmt Ltd Limited Liability Company holds 302,100 shares. Schwab Charles Management Inc reported 0% in Akebia Therapeutics, Inc. (NASDAQ:AKBA). Citadel Advisors Ltd Llc accumulated 229,314 shares. Manufacturers Life The invested 0% in Akebia Therapeutics, Inc. (NASDAQ:AKBA). Citigroup Inc owns 35,859 shares. Metropolitan Life Insurance Ny has 14,181 shares. Perceptive reported 2.46 million shares stake. Morgan Stanley reported 1.17M shares.

Since February 15, 2018, it had 0 insider purchases, and 1 insider sale for $14,620 activity.

Analysts expect Akebia Therapeutics, Inc. (NASDAQ:AKBA) to report $-0.51 EPS on August, 14.They anticipate $0.02 EPS change or 3.77 % from last quarter’s $-0.53 EPS. After having $-0.48 EPS previously, Akebia Therapeutics, Inc.’s analysts see 6.25 % EPS growth. The stock decreased 1.00% or $0.1 during the last trading session, reaching $9.95. About 491,115 shares traded. Akebia Therapeutics, Inc. (NASDAQ:AKBA) has declined 25.63% since July 14, 2017 and is downtrending. It has underperformed by 38.20% the S&P500.

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics to patients with kidney disease through hypoxia-inducible factor biology. The company has market cap of $566.29 million. The Company’s lead product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia related to chronic kidney disease in non-dialysis and dialysis patients. It currently has negative earnings. The firm is also developing a HIF portfolio of product candidates that include AKB-6899 for the treatment of anemia; and AKB-5169, a preclinical compound for the treatment for inflammatory bowel disease.

More news for Akebia Therapeutics, Inc. (NASDAQ:AKBA) were recently published by: Seekingalpha.com, which released: “Akebia Therapeutics, Keryx Biopharma agree to merge” on June 28, 2018. Seekingalpha.com‘s article titled: “Keryx Biopharmaceuticals And Akebia Therapeutics: Was The Reaction To The Merger Announcement Justified?” and published on July 06, 2018 is yet another important article.

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.